Given the promising results from clinical trials assessing the immunotherapy of advanced or treatment-refractory cancer with immune checkpoint inhibitors such as anti-PD-1/PD-L1, the B7 and TNFR family members may be closely evaluated as potential immunotherapeutic targets in HCC. This evidence concerns the gene PDCD1 and cancer.